Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
TKT to Report Fourth Quarter and Year-End 2004 Financial Results
on February 23, 2005
CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) will announce its fourth quarter and year-end 2004 financial
results on February 23, 2005 before the open of U.S. financial markets. In
connection with this announcement, TKT will host a conference call and live
audio webcast on February 23, 2005 at 10:00 a.m. Eastern Time to discuss its
fourth quarter and full year 2004 financial results and financial outlook for
2005.
Participants may access the call by dialing (913) 981-5533. This call will also
be broadcast live over the Internet at http://www.tktx.com/ under the Investor
Information section. Please dial in 5 to 10 minutes prior to the scheduled
conference call time or log on to the website at least 15 minutes prior to the
call in order to register, download, and install any necessary software.
A replay of this conference call will be available for two weeks, beginning
February 23, 2005 at 1:00 p.m. Eastern Time by dialing (719) 457- 0820 and
using the access code 6847230. In addition, a replay of the webcast will be
archived on the TKT website under Events in the Investor Information section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html